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Abstract
Chemokines have been found to exert direct, defensin-like antimicrobial activity in vitro, suggesting that, in addition to
orchestrating cellular accumulation and activation, chemokines may contribute directly to the innate host response against
infection. No observations have been made, however, demonstrating direct chemokine-mediated promotion of host
defense in vivo. Here, we show that the murine interferon-inducible CXC chemokines CXCL9, CXCL10, and CXCL11 each
exert direct antimicrobial effects in vitro against Bacillus anthracis Sterne strain spores and bacilli including disruptions in
spore germination and marked reductions in spore and bacilli viability as assessed using CFU determination and a
fluorometric assay of metabolic activity. Similar chemokine-mediated antimicrobial activity was also observed against fully
virulent Ames strain spores and encapsulated bacilli. Moreover, antibody-mediated neutralization of these CXC chemokines
in vivo was found to significantly increase host susceptibility to pulmonary B. anthracis infection in a murine model of
inhalational anthrax with disease progression characterized by systemic bacterial dissemination, toxemia, and host death.
Neutralization of the shared chemokine receptor CXCR3, responsible for mediating cellular recruitment in response to
CXCL9, CXCL10, and CXCL11, was not found to increase host susceptibility to inhalational anthrax. Taken together, our data
demonstrate a novel, receptor-independent antimicrobial role for the interferon-inducible CXC chemokines in pulmonary
innate immunity in vivo. These data also support an immunomodulatory approach for effectively treating and/or preventing
pulmonary B. anthracis infection, as well as infections caused by pathogenic and potentially, multi-drug resistant bacteria
including other spore-forming organisms.
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Introduction
The pulmonary airways represent a major site of interaction
between the mammalian host and microbial pathogens. Infection
resulting from the exposure of the respiratory tract to a variety of
microorganisms is opposed by pulmonary innate immunity, a
complex host response that protects against infection by directly
mediating initial host defense in the airspace while helping to shape
the activation of adaptive immunity [1,2]. Among the primary
components of innate immunity are secreted mediators including
chemokines, small proteins produced mainly by epithelial and
phagocytic cells in response to pattern-recognition receptor
engagement and pro-inflammatory cytokines [3]. Chemokines were
originally recognized for their ability to induce directed migration of
leukocytes and facilitate controlled cellular accumulation and
activation during an inflammatory response through receptor-
dependent interactions between chemokines and their specific G-
protein-coupled receptor(s) expressed by responsive cells [4].
In addition to their role in cellular recruitment, a number of
chemokines have been found to mediate direct antimicrobial
effects against a broad range of Gram-positive and Gram-negative
bacteria in vitro [5–8]. While the mechanistic details of these
effects remain undefined, antimicrobial activity is thought to result
from interactions between positively-charged regions present at
the chemokine’ C-terminus and negatively-charged moieties at the
microbial cell surface, resulting in cell lysis [8]. Although
chemokines have been shown to be central components of the
host response to pulmonary infection [9], these molecules have
primarily been viewed in the context of receptor/ligand
interactions, without consideration for direct ligand-mediated
antimicrobial activity. As such, the biological relevance of
receptor-independent, chemokine-mediated antimicrobial activity
in host defense in vivo remains to be established.
The disease anthrax is caused by the Gram-positive, spore
forming bacterium Bacillus anthracis. The infectious B. anthracis
spore consists of distinct, concentric layers that encase the spore’s
PLoS Pathogens | www.plospathogens.org 1 November 2010 | Volume 6 | Issue 11 | e1001199genomic material and provide protection against multiple stresses
including high temperature and lytic digestion [10,11]. Depending
on the spore’s route of entry, B. anthracis causes three distinct types
of disease: inhalational, gastrointestinal, and cutaneous anthrax.
Inhalational anthrax results as a consequence of spore deposition
within the host airspace. Here, spores encounter effectors of host
innate immunity and are taken up by phagocytes including
macrophages [12] and dendritic cells [13]. It is thought that spore
germination, the resumption of metabolic activity and outgrowth
as a vegetative cell, begins following phagocytosis at these localized
sites of infection [14,15] and that the vast majority of germinating
organisms are killed [16]. During transit by phagocytic cells to the
regional lymph nodes, however, a small subset of surviving bacilli
are believed to mediate membrane disruptive events allowing
escape from phagocytic vesicles and, subsequently, the phagocytic
cell [17]. Extracellular bacilli evade host immune responses
through the production of two principle, plasmid-encoded
virulence factors: a tripartite toxin encoded by pXO1 and
responsible for broadly suppressing the host immune response
[18], and a poly-D-glutamic acid capsule encoded by pXO2, that
protects against phagocytic killing [19]. These and other bacterial
factors allow B. anthracis to multiply rapidly, resulting in systemic
dissemination, toxemia, and death of the infected host [20].
CXCL9, CXCL10, and CXCL11 are homologous, interferon-
inducible members of the CXC chemokine family that lack the
tripeptide structure/function motif Glu-Leu-Arg (ELR) important
in neutrophil chemoattraction [9]. As such, these interferon-
inducible ELR
- CXC chemokines signal through a common
receptor, CXCR3, to facilitate selective recruitment of mononu-
clear leukocytes, natural killer cells, and plasmacytoid dendritic
cells to sites of inflammation [9,21]. We [22] and others [5,8] have
previously reported the ability of human CXCL9, CXCL10, and
CXCL11 to exert direct antimicrobial activity against B. anthracis,
as well as Escherichia coli, Listeria monocytogenes, and Staphylococcus
aureus. Furthermore, we have observed that CXC chemokine
induction in the lungs of C57BL/6 mice challenged intranasally
with B. anthracis Sterne strain spores is associated with significant
reductions in spore germination and subsequent disease progres-
sion [22]. Based on these observations, we hypothesized that
murine CXCL9, CXCL10, and CXCL11 exert direct antimicro-
bial effects against B. anthracis and thereby mediate a receptor-
independent contribution to host defense against pulmonary B.
anthracis infection.
In the present study, we demonstrate that the murine
interferon-inducible ELR
- CXC chemokines CXCL9, CXCL10,
and/or CXCL11 exert direct antimicrobial effects against
toxigenic, unencapsulated B. anthracis Sterne strain (pXO1
+
pXO2
2) as well as toxigenic, capsule-forming Ames strain
(pXO1
+ pXO2
+) spores and bacilli. Furthermore, we show that
neutralization of these CXC ligands, but not their shared cellular
receptor CXCR3, in C57BL/6 mice challenged with B. anthracis
Sterne strain spores significantly increases host susceptibility to
inhalational anthrax. These observations support that the CXC
chemokines directly contribute to host defense against pulmonary
B. anthracis infection in vivo, providing unique insight into the
effector mechanisms of the innate host response to bacterial
infection. These data also support the consideration of antimicro-
bial chemokines in the development of novel, therapeutic
strategies for countering multidrug resistant pathogens.
Results
Murine CXCL9, CXCL10, and CXCL11 exert direct
antimicrobial effects against B. anthracis Sterne strain
spores and bacilli
As the induction of the interferon-inducible ELR
- CXC
chemokines within the lungs of spore-challenged mice is associated
with resistance to inhalational anthrax [22], we sought to
determine whether murine CXCL9, CXCL10, and CXCL11
exert antimicrobial activity against B. anthracis Sterne strain.
Included in these studies were two control murine CC family
chemokines, CCL2 and CCL5, whose molecular weights and basic
isoelectric points are similar to the CXC chemokines examined
[5]. Disruptions in spore germination and bacterial cell viability
were assessed using colony-forming unit (CFU) determination,
performed in the presence or absence of heat treatment to
differentiate between heat-resistant spores and heat-sensitive
bacilli.
By 6 h post-treatment, untreated, CCL2- and CCL5-treated
spores underwent considerable germination and vegetative
outgrowth as evidenced by a loss of heat-resistant CFU
(germination) and an increase in heat-sensitive CFU (vegetative
growth) as compared to the initial inoculum (Figure 1A).
Treatment of B. anthracis spores with CXCL9 resulted in an
approximate 1,000-fold reduction in viable organisms as com-
pared to the untreated control. Retention of spore dormancy was
observed to be significantly greater in the presence of CXCL9, yet
viable spores represented less than 10% of the initial inoculum;
interestingly, this reduction in viable spores did not coincide with
an appearance of heat-sensitive, germinated organisms. These
effects were concentration dependent (EC50 =5.0061.10 mg/ml;
Figure S1A,B) and suggest that CXCL9 inhibits spore germina-
tion and disrupts the maintenance of spore viability. In support
of this notion, CXCL9-treated spores demonstrated a lack of
primary outgrowth as determined by microscopic visualization
(Figure 1B), and the resumption of metabolism (a hallmark of
spore germination) was absent in CXCL9-treated spore samples
6 h post-treatment as measured by an Alamar Blue based assay of
metabolism (Figure 1C). Treatment of B. anthracis spores with
CXCL10 or CXCL11 resulted in significantly decreased levels of
heat-resistant organisms and an approximate 10-fold reduction in
Author Summary
Innate immunity is critical to host defense and plays a
central role in protecting the lungs from respiratory
pathogens. Among the mediators important in the innate
host response to pulmonary infection are chemokines,
proteins originally described for their ability to regulate
immune cell trafficking during an inflammatory response.
More recently, chemokines have been found to exert
direct antimicrobial activity against a broad range of
bacteria and fungi in vitro. While these observations
suggest chemokines may contribute to host defense by
killing microorganisms at local sites of infection through
activities not associated with cellular chemokine receptors,
the biological relevance of direct chemokine-mediated
antimicrobial activity in vivo has not been established.
Here we show that the murine chemokines CXCL9,
CXCL10, and CXCL11 exert direct antimicrobial effects
against B. anthracis in vitro and that neutralization of these
CXC chemokines, but not their shared receptor CXCR3,
increases host susceptibility to pulmonary B. anthracis
infection in vivo. These data provide unique insight into
the host mediators important in host-pathogen interaction
and pathogenesis of disease and support the emerging
concept that host chemokines mediate efficient, pleiotro-
pic roles that include receptor-independent promotion of
host defense in vivo.
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PLoS Pathogens | www.plospathogens.org 2 November 2010 | Volume 6 | Issue 11 | e1001199Figure 1. Direct chemokine-mediated antimicrobial effects against B. anthracis Sterne strain spores and bacilli. Murine CXCL9, CXCL10,
and CXCL11 display direct antimicrobial activity against B. anthracis Sterne strain (pXO1
+ pXO2
2) organisms. (A) Quantification of direct chemokine-
mediated disruptions of Sterne strain spore germination, viability, and primary outgrowth. CFU determination was performed 6 h post-treatment in
the presence or absence of heat treatment. Data represent mean 6 SEM; dotted line indicates the initial inoculum. Similar results were observed in
three independent experiments. ***p,0.001 compared to untreated control. (B) Microscopic visualization of untreated and CXCL9-treated
B. anthracis spores 6 h post-treatment. Representative fields from six independent experiments are shown at 2006 magnification. (C) Metabolic
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(Figure 1A). While possibly exerting a sporicidal effect, neither
CXCL10 or CXCL11 was found to block spore germination
(Figure 1A,C). Chemokine-mediated antimicrobial activity
against B. anthracis Sterne strain bacilli was also observed, with
all three interferon-inducible ELR
- CXC chemokines capable of
mediating significant decreases in vegetative cell viability as
determined by both CFU analysis (Figure 1D) and Alamar Blue
reduction (Figure 1E). CXCL9 demonstrated considerable
bactericidal activity, mediating the complete killing of the initial
bacilli inoculum in a concentration-dependent manner (EC50
=3.9660.75 mg/ml; Figure S1C,D). Of note, the antimicrobial
hierarchy of the murine CXC chemokines presented here
(CXCL9 .. CXCL10 < CXCL11) is distinct from the hierarchy
previously observed for the human CXC chemokines (CXCL10$
CXCL9 .. CXCL11) [22].
Antimicrobial effects of interferon-inducible ELR
- CXC
chemokines against B. anthracis Ames strain spores and
encapsulated bacilli
In contrast to B. anthracis Sterne strain organisms, vegetative
Ames strain bacilli carry the capsule biosynthetic operon encoded
by pXO2 and are capable of generating a protective poly-D-
glutamic acid capsule. While the increased virulence of encapsu-
lated organisms has primarily been attributed to enhanced
bacterial evasion of cell-mediated host responses [19], the capsule
may act as a barrier against soluble immune mediators. Therefore,
the antimicrobial potential of murine CXCL9 against fully virulent
B. anthracis Ames strain organisms was examined using CFU
determination. Also, as the ability of human ELR
- interferon-
inducible CXC chemokines to mediate antimicrobial effects
against B. anthracis Ames strain is unknown, we sought to
determine the capacity of human CXCL10 to directly target fully
virulent spores and encapsulated bacilli relevant to human disease;
human CXCL10 has previously been shown to exert antimicrobial
effects against B. anthracis Sterne strain organisms similar to those
reported here for murine CXCL9 [22].
Treatment of Ames strain spores with murine CXCL9 or
human CXCL10 was found to result in significantly reduced levels
of spore germination and primary outgrowth as compared to the
untreated control (Figure 2A), supporting a lack of a role for
pXO2-encoded components in spore susceptibility to these
chemokines. We next examined the ability of murine CXCL9
and human CXCL10 to exert a direct bactericidal effect against
toxigenic, encapsulated bacilli. Treatment of encapsulated Ames
strain bacilli with murine CXCL9 resulted in an approximate 100-
fold reduction in bacterial viability as compared to the untreated
control 6 h post-treatment (Figure 2B). Similarly, human
CXCL10 was found to display antimicrobial activity against
encapsulated bacteria, mediating a five-log reduction in viable
vegetative cells. Ames strain bacilli were visualized in India ink
preparations, confirming that the initial bacilli inoculum consisted
of encapsulated bacterial cells, and that the capsule was not lost
under experimental conditions (Figure 2C). That murine
CXCL9 and human CXCL10 exert direct antimicrobial effects
against Ames strain spores and encapsulated bacilli, and that these
effects are similar to those observed for Sterne strain organisms
indicate B. anthracis Sterne strain is an appropriate model organism
for studying chemokine-mediated antimicrobial activity against
this pathogen.
The interferon-inducible ELR
- CXC chemokines directly
contribute to host defense against pulmonary B.
anthracis infection
In order to determine the biological relevance of direct
chemokine-mediated antimicrobial activity during pulmonary B.
anthracis infection, we used a murine model of inhalational anthrax
in which endogenous CXCL9, CXCL10, and/or CXCL11, or
their shared cellular receptor CXCR3 were selectively neutralized.
Antibody-mediated neutralization was performed in C57BL/6
mice (relatively resistant to inhalational infection by B. anthracis
Sterne strain) and was achieved through intraperitoneal (i.p.)
administration of anti-sera raised against individual interferon-
inducible ELR
- CXC chemokines or the NH2 terminus of
CXCR3 [23,24]. These antibodies were previously shown to be
specific without cross-reactivity to a panel of cytokines and other
chemokine ligands [23].
Neutralization of endogenous CXCL9 in B. anthracis spore-
challenged animals was found to significantly increase host
susceptibility to pulmonary infection (p=0.012) resulting in
approximately 30% mortality as compared to spore-challenged
animals receiving control serum, ,5% mortality (Figure 3);
administration of CXCL9 neutralizing serum in the absence of
infection was not found to cause death, with 12/12 mice surviving
beyond 20 days. Neutralization of CXCL10 in spore-challenged
animals resulted in decreased host survival (20% mortality) that
approached statistical significance (p=0.064) when compared to
infected animals receiving control serum; similar mortality was
observed in CXCL10
-/- mice following spore challenge (data not
shown). CXCL11 neutralization was not found to increase host
susceptibility to inhalational anthrax. Combinatorial neutraliza-
tion of CXCL9 together with CXCL10 or CXCL10/CXCL11
during pulmonary B. anthracis infection significantly increased host
susceptibility to anthrax, with neutralization of all three CXC
chemokines resulting in 50% mortality (p=0.0003).
Importantly, antibody-mediated neutralization of CXCR3
(Figure S2) did not result in increased susceptibility to pulmonary
B. anthracis infection (Figure 3), and survival among spore-
challenged CXCR3
-/- and wild-type animals was the same (data not
shown). These data suggest that direct ligand-mediated effects not
associated with CXCR3 contribute to limiting disease progression
in this model of pulmonary infection. Indeed, the post-challenge
induction of endogenous CXCL9, CXCL10, and CXCL11
previously associated with resistance to inhalational B. anthracis
infection [22] was maintained in animals receiving CXCR3
neutralizing serum (Figure S3). Additionally, host inflammatory
cell populations in the lungs of spore-challenged animals receiving
CXCL9/CXCL10/CXCL11 or CXCR3 neutralizing sera were
strikingly similar following challenge (Figure S4); the absence of
significant differences in host cell populations indicate that
CXCR3-dependent, cell-mediated effects are not responsible for
the distinct differences in disease progression between these
activity as an index of spore germination, viability, and vegetative growth. Alamar Blue reduction was measured 6 h post-treatment and is expressed
as percent control; bars represent mean 6 SEM for three independent experiments. **p,0.01 ***p,0.001 compared to untreated control. (D and E)
Chemokine-mediated antimicrobial effects against B. anthracis Sterne strain bacilli as measured by CFU determination (D) and Alamar Blue analysis
(E). CFU data represent the mean 6 SEM. A representative data set is shown from three separate experiments; initial inoculum (dotted line), n.d. =
none detected. Alamar Blue data are expressed as percent control and represent mean values 6 SEM for three independent experiments. ***p,0.001
compared to untreated control.
doi:10.1371/journal.ppat.1001199.g001
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antimicrobial role for the interferon-inducible ELR
- CXC
chemokines during pulmonary B. anthracis infection that is
independent of CXCR3-mediated cellular recruitment to sites of
infection.
Interferon-inducible ELR
- CXC chemokine neutralization
is associated with B. anthracis dissemination and toxemia
To gain insight into disease progression associated with the
neutralization of CXCL9, CXCL10, and CXCL11, and to
confirm that host death resulted as a consequence of B. anthracis
infection, we investigated two salient features of anthrax: bacterial
dissemination and toxemia. The ability of B. anthracis to disse-
minate from initial sites of infection was examined by measuring
B. anthracis CFU in the lungs, kidneys, spleen, and liver from
moribund mice receiving CXCL9/CXCL10/CXCL11 neutraliz-
ing sera, as compared to those measured from paired, spore-
challenged animals receiving control serum.
Consistent with previously published reports measuring bacte-
rial dissemination during pulmonary B. anthracis infection [25,26],
B. anthracis CFU in the lungs of spore-challenged animals were
approximately equivalent between treatment groups. However, in
contrast to control animals, which showed little evidence of
extrapulmonary dissemination, tissues harvested from animals
receiving CXCL9/CXCL10/CXCL11 neutralizing sera demon-
strated widespread bacterial dissemination with considerable CFU
detected in the kidneys, spleen, and liver (Figure 4). This
observed dissemination is consistent with bacterial dissemination
previously reported for strains of mice highly susceptible to Sterne
strain infection [20]. The ability of the CXC chemokines to
participate in limiting disease progression prior to systemic
invasion was also observed using in vivo imaging. C57BL/6 mice
were challenged with a bioluminescent strain of B. anthracis
(7702-lux) whose vegetative cells are constitutively luminescent and
allow visualization of bacterial dissemination [27]. As above, only
upon neutralization of CXCL9, CXCL10, and CXCL11 was
systemic disease observed as evidenced by detection of lumines-
cence in tissues distant to the host airways (Figure 5A,B). Also,
extrapulmonary dissemination was observed to occur after the
establishment of infection in the chest (Figure C,D) consistent
with impaired host defense at local sites of infection.
Toxemia is characteristic of systemic anthrax and results from
the secretion of a tripartite toxin consisting of the receptor binding
component protective antigen (PA), and two catalytically active
components, the metalloprotease lethal factor (LF) and the
adenylate cyclase edema factor (EF) [18]. Several animal studies
examining the production of PA and LF during infection have
found PA to be detectable in the blood of infected animals only
Figure 2. Chemokine-mediated antimicrobial activity against B. anthracis Ames strain spores and encapsulated bacilli. Murine CXCL9
and human CXCL10 display direct antimicrobial activity against B. anthracis Ames strain (pXO1
+ pXO2
+) organisms. (A) Chemokine-mediated effects
on Ames strain spore germination, viability, and primary outgrowth. CFU determination was performed 6 h post-treatment in the presence or
absence of heat treatment. Data represent mean 6 SEM; dotted line indicates initial inoculum. A representative data set is shown from three
independent experiments. **p,0.01 ***p,0.001 compared to untreated control. (B) Direct antimicrobial effects of murine CXCL9 and human CXCL10
against encapsulated Ames strain bacilli. Bacterial cell viability was measured using CFU determination performed 6 h post-treatment. Data represent
mean values 6 SEM; initial inoculum (dotted line). Similar results were observed in three independent experiments. ***p,0.001 compared to
untreated control. (C) Microscopic visualization of encapsulated Ames strain bacilli in India ink preparations. Capsules appear as defined clear zones
around the bacterial cells. Representative fields from two independent experiments are shown at 2006magnification.
doi:10.1371/journal.ppat.1001199.g002
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to reflect rapid binding of PA by host cells [29]. Conversely, LF
has been shown to accumulate earlier in infection, consistent with
delayed internalization (cellular entry of LF depends upon prior
PA binding, activation, and heptamerization), providing a good
measure of toxemia during disease progression [28]. As an index
of toxemia, we used an established mass spectrometry-based
method [30] to detect and measure the levels of biologically active
LF in serum collected from spore-challenged mice. Whereas
infected control animals showed low or undetectable levels of LF,
serum collected from spore-challenged animals receiving CXCL9/
CXCL10/CXCL11 neutralizing sera was found to contain
concentrations of active LF ranging from 25–400 ng/ml
(Figure 6), levels commensurate with concentrations measured
from the sera of nonhuman primates that have succumbed to
inhalational anthrax [30]. These data indicate that the interferon-
inducible ELR
- CXC chemokines help protect against pulmonary
B. anthracis infection in a murine model of infection, and that
disruption of innate, ligand-mediated roles in host defense
increases susceptibility to invasive disease and toxemia.
Discussion
Exposure of the host lungs to potentially pathogenic microor-
ganisms represents a significant immunological challenge for host
defense. Initial encounters between inhaled microbes and
components of pulmonary innate immunity initiate a dynamic
set of interactions that ultimately determines whether disease will
occur [31]. The host response to infection is coordinated, in part,
through the production of chemokines that allow controlled
cellular accumulation and activation during an immune response
[32]. Some chemokine ligands display direct antimicrobial activity
in vitro [33] raising the possibility of a multifunctional role for
chemokines in host defense that includes microbial killing at local
sites of host-pathogen interaction. Here, we investigated the ability
of the interferon-inducible ELR
- CXC chemokines to directly
contribute to host defense against pulmonary B. anthracis infection.
We found that CXCL9, CXCL10, and CXCL11 each exert direct
antimicrobial effects against B. anthracis in vitro and that
neutralization of endogenous CXCL9, individually or together
with CXCL10 or CXCL10/CXCL11, but not CXCR3, signifi-
cantly increases host susceptibility to inhalational anthrax in a
murine model of infection. Our data support a novel, CXCR3-
independent role for the interferon-inducible ELR
- CXC chemo-
kines in the innate host response against pulmonary B. anthracis
infection that is consistent with direct chemokine-mediated
antimicrobial activity at local sites of infection.
Each murine CXC chemokine examined in vitro for antimi-
crobial activity was found to exert direct antimicrobial effects
against B. anthracis Sterne strain spores and bacilli. In vitro analysis
also demonstrated the ability of murine CXCL9 and human
CXCL10 to exert direct antimicrobial effects against fully virulent
B. anthracis Ames strain spores and encapsulated bacilli. Interest-
ingly, while Ames strain spores were found to be fully susceptible
to murine CXCL9, direct killing of encapsulated bacilli by murine
CXCL9 was reduced compared to unencapsulated organisms. As
CXCL9 contains a relatively extended C-terminal region [5], the
relative reduction in antimicrobial activity may result from greater
exclusion of CXCL9 by the poly-D-glutamic acid capsule thereby
preventing the chemokine from reaching the presumed site(s) of
action at the bacterial surface. While this difference may impact
the defensive role of CXCL9 during infection with fully virulent B.
anthracis, the in vitro data presented here demonstrate that
chemokine-mediated antimicrobial activity is applicable to both
strains of B. anthracis examined. Given that the activity of many
antimicrobial chemokines and host peptides is disrupted by the
presence of serum and/or physiological concentrations of ions
including Na
+,K
+, and Mg
2+ [33,34], it is important to note that
the in vitro antimicrobial activity of CXCL9, CXCL10, and
CXCL11 against B. anthracis was tested in culture medium
containing physiologically relevant concentrations of serum
Figure 3. Host susceptibility to pulmonary B. anthracis infection. Neutralization of the interferon-inducible ELR
- CXC chemokines, but not their
shared cellular receptor, significantly increases host susceptibility to inhalational anthrax. Mortality was measured among C57BL/6 mice challenged
intranasally with B. anthracis Sterne strain spores and receiving control serum or neutralizing serum against the indicated CXC chemokine ligand(s) or
their receptor CXCR3. Kaplan-Meier survival curve represents combined mortality from $ two independent challenges of 8–12 animals per group,
24–32 animals total per group. Similar results were observed in each independent experiment. *p,0.05 **p,0.01 ***p,0.001 as compared to spore-
challenged animals receiving control serum.
doi:10.1371/journal.ppat.1001199.g003
CXC Chemokines and Pulmonary Infection
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to those found in airway surface fluid [35], supporting the
potential of the interferon-inducible ELR
- CXC chemokines to
mediate antimicrobial activity in the host airways.
Previous work by our laboratory has demonstrated that the
induction of the interferon-inducible ELR
- CXC chemokines
within the lungs following B. anthracis spore challenge is associated
with significant reductions in spore germination and resistance to
pulmonary infection [22]. In the present study, we investigated the
consequences of selectively neutralizing CXCL9, CXCL10, and/
or CXCL11 during pulmonary B. anthracis infection, and whether
potential ligand-mediated contributions to host defense were
independent of interactions with CXCR3. Consistent with its
potent antimicrobial activity in vitro and its sustained induction
within the lungs following spore challenge in vivo (Figure S3;
[22]), neutralization of endogenous CXCL9 resulted in signifi-
cantly increased host susceptibility to inhalational anthrax. While
individual neutralization of CXCL10 or CXCL11 was not found
to result in significantly increased mortality among spore-
challenged animals, combined neutralization of CXCL9 together
with CXCL10 or CXCL10/CXCL11 indicated potential additive
effects in promoting host defense against pulmonary B. anthracis
infection, with neutralization of all three CXC ligands resulting in
widespread bacterial dissemination, toxemia, and the highest
mortality of any spore-challenged group examined in this study.
Importantly, CXCR3 neutralization, which disrupts receptor-
mediated cellular recruitment in response to these CXC
chemokines, was not found to increase host susceptibility to
inhalational anthrax. These results demonstrate the ability of the
interferon-inducible ELR
- CXC chemokines, in particular
CXCL9, to contribute directly to host defense through activities
not associated with CXCR3. Moreover, these observations
support the potential of an efficient, multifunctional role for host
chemokines that may represent a more generalized mechanism of
the innate host response against infection.
While the data presented here are consistent with direct
chemokine-mediated antimicrobial activity in vivo, chemokine
ligand concentrations measured from lung homogenates of spore-
challenged animals are not as high as those required to achieve
antimicrobial effects in vitro. In fact, with few exceptions, most
known antimicrobial chemokines and host peptides, including
many defensins, exert direct bactericidal effects in vitro at
relatively high concentrations; minimal inhibitory concentrations
typically range from 0.1–100 mg/ml [36]. Numerous studies,
however, have identified roles for antimicrobial host peptides in
pulmonary defense against bacterial infection suggesting biologi-
cally relevant concentrations do occur during infection [37]. The
ability of the interferon-inducible ELR
- CXC chemokines to
mediate direct antimicrobial activity in vivo is most likely relevant
at local sites of host-pathogen interaction. At these inflammatory
Figure 4. Dissemination of B. anthracis from initial sites of infection in the airways. Increased host susceptibility to inhalational anthrax
upon neutralization of CXCL9, CXCL10, and CXCL11 is characterized by widespread bacterial dissemination following spore challenge as detected and
measured using CFU determination. B. anthracis titers in the lungs, kidneys, spleen, and liver were measured from moribund animals receiving
CXCL9/CXCL10/CXCL11 neutralizing sera and from paired, spore-challenged animals receiving control serum (5–7 animals per group). CFU values
from individual mice are shown for the indicated tissue 6 heat treatment; solid lines represent the median for each group. Data points along the
X-axis represent values below the limit of detection, 50 CFU/ml. For each tissue examined, median chemokine-neutralized CFU values in the absence
of heat treatment were significantly greater than those determined for control mice (p,0.01), except lung (p=0.5).
doi:10.1371/journal.ppat.1001199.g004
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expected to result in substantial chemokine concentrations capable
of mediating direct contributions to host defense [1]. This notion is
supported by the ability of epithelial [38,39] and mononuclear
cells [5] to produce significant amounts of CXCL9, CXCL10,
and/or CXCL11 in response to inflammatory stimuli, with
concentrations of CXCL9 and CXCL10 reaching several hundred
nanograms per milliliter [39]. Furthermore, tonsil fluid collected
from patients with Streptococcus pyogenes pharyngitis contains
CXCL9 concentrations exceeding those required to kill S. pyogenes
in vitro, and the inhibition of CXCL9 expression reduces
antimicrobial activity against this organism at the surface of
inflamed pharyngeal cells [38]. CXCL9 may be of particular
importance in promoting host defense against bacterial infection as
it is strongly induced in several murine models of pulmonary
infection including Klebsiella pneumoniae and Mycobacterium tuberculosis
[9,40]. Similarly, and of particular relevance to the current study,
adults exposed to B. anthracis spores (based on positive nasopha-
ryngeal swab cultures) in the U.S. Capitol building during the
2001 anthrax attacks demonstrated elevated levels of several
inflammatory mediators including CXCL9 [41].
The ability of CXCL9 to mediate a multifunctional role in host
defense is supported by observations that S. pyogenes and the
opportunistic pathogen Finegoldia magna each release specific
virulence factors believed to promote immune evasion by
disrupting the integrity or availability of the C-terminal region of
CXCL9, thereby reducing or abolishing direct antimicrobial
activity [38,42]. Interestingly, while these factors limit CXCL9-
mediated antimicrobial activity, the ability of CXCL9 to signal
through CXCR3 is largely retained, demonstrating separate and
distinct chemokine-mediated functions independently disrupted by
pathogens. That other antimicrobial chemokines are similarly
targeted [43] further indicates that endogenously produced host
chemokines mediate multifunctional roles in host defense that
likely represent a more generalized mechanism of the innate host
response to infection. Indeed, murine CCL6 and its human
homologs were recently found to be highly expressed in the
intestinal mucosa and capable of mediating antimicrobial effects
against a subset of intestinal bacteria ex vivo [44]. In addition, the
antimicrobial chemokine CCL28 has been found to be constitu-
tively expressed and highly concentrated in mucosal secretions [6],
and CXCL9 from seminal plasma possesses antimicrobial activity
against the urogenital pathogen Neisseria gonorrhoeae [45]. These
observations are each consistent with direct chemokine-mediated
roles in host defense and support the notion of host chemokines as
multifunctional effectors of innate immunity.
It remains to be determined at what point in pulmonary B.
anthracis infection the interferon-inducible ELR
- CXC chemokines
Figure 5. In vivo imaging of B. anthracis dissemination in animals receiving CXCL9/CXCL10/CXCL11 neutralizing sera. (A–D)
Bioluminescence detected and measured in groups of mice challenged intranasally with B. anthracis 7702-lux. Animals receiving CXCL9/CXCL10/
CXCL11 neutralizing sera demonstrated considerable bacterial dissemination as evidenced by the detection of luminescence in multiple organs
(panel A, animal 4). Systemic dissemination was found to occur after the establishment of localized infection (panel C, animal 3; dashed circle).
Bioluminescence was not observed in paired, spore-challenged animals receiving control serum (panels B and D). Animals were imaged every other
day for 10 d post-challenge; merged luminescent and photographic images are shown. Luminescence is reported as photons per second per square
centimeter per steradian (n=12 animals per group).
doi:10.1371/journal.ppat.1001199.g005
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CXCL10 are each induced to relatively high levels within the
lungs following spore challenge suggesting that antimicrobial
activity may act early in infection against the spore form of the
organism. Antimicrobial activity against B. anthracis spores during
infection is consistent with the previously reported association
between CXCL9, CXCL10, and CXCL11 induction and
decreased spore germination in vivo [22], as well as observations
that the reduction of spore burden on resident macrophages is
important in preventing intracellular vegetative outgrowth and
subsequent disease progression [46]. Spore challenge with
toxigenic, unencapsulated B. anthracis results in spore germination
and the establishment of infection at local sites within the host
airways [14,15]. Infection is initially contained here providing an
opportunity for chemokine-mediated antimicrobial activity against
vegetative bacilli prior to extrapulmonary dissemination [20].
While the observations reported here are consistent with direct
antimicrobial effects similar to those found in vitro, they do not
preclude ligand-mediated immunomodulatory activity; CXCL9
has recently been reported to induce gene transcription and
chemokine production in peripheral blood mononuclear cells,
independent of interactions with CXCR3 [47]. As inhalational
anthrax is an acute disease capable of abrogating host immune
responses suggests that host chemokines mediate important roles
in the innate host response of naı ¨ve hosts and help to limit
infection early in disease progression.
The continuing emergence of antibiotic resistance [48] and the
potential of engineered resistance in the weaponization of
biological agents [49] represent serious areas of concern. The
ability of host defense peptides to exert direct antimicrobial effects
and promote protective immunity has been suggested as a
template for the development of novel therapeutic strategies
capable of addressing these challenges [50]. Certain chemokines
(including CXCL9, CXCL10, and CXCL11) share many
structural and functional relationships with host defense peptides,
suggesting that these mediators have overlapping roles in host
defense and similar therapeutic potential [51]. The ability of type 1
(IFN-a/b) and type 2 (IFN-c) interferons to strongly induce ELR
-
CXC chemokine production supports the administration of
exogenous interferon as a therapeutic strategy for treating
pulmonary B. anthracis infection. Indeed, both IFN-a/b and
IFN-c have been found to promote protection against B. anthracis
challenge in vitro [52] and in vivo [53]. While neither of these studies
examined CXC chemokines, each supports the potential thera-
peutic application of exogenous chemokine induction in post-
exposure prophylaxis or the treatment of anthrax. Furthermore,
the exogenous induction of host chemokines capable of activating
cellular immunity, promoting immune mediator production, and
directly killing pathogens may apply more broadly to the
development of innovative therapeutic avenues for the treatment
of pathogenic and potentially, multidrug-resistant bacterial
infections.
In summary, our findings provide strong evidence for an
important CXCR3-independent role for the interferon-inducible
ELR
- CXC chemokines in the innate host response against
pulmonary B. anthracis infection, and indicate that CXCL9, in
particular, may function as one of the major antimicrobial
components of the inflamed host airway. Neutralization of the
CXC chemokine ligands, but not their shared cellular receptor,
was found to disrupt the host’s ability to limit disease progression
and contain B. anthracis at initial sites of infection, resulting in
increased susceptibility to inhalational anthrax characterized by
systemic dissemination, toxemia, and death. While further studies
are required to define the biologically relevant contributions of the
interferon-inducible ELR
- CXC chemokines to host defense, the
ability of an intact host chemokine response to directly promote
the innate host response against inhalational anthrax is consistent
with direct antimicrobial activity as observed for these chemokines
in vitro. Direct chemokine-mediated antimicrobial activity at the
interface of host-pathogen interaction may represent an important
mechanism in host defense, and supports the consideration of host
chemokines in the development of novel, immunomodulatory
therapeutic strategies.
Materials and Methods
Ethics statement
Animal studies were carried out in strict accordance with the
US Public Health Service Policy on the Humane Care and Use of
Laboratory Animals (PHS Assurance #A3245-01), the US
Department of Agriculture Animal Welfare Act (USDA Registra-
tion #52-R-0011), and the US Government Principles for the
Utilization and Care of Vertebrate Animals Used in Testing,
Research, and Training. Animal protocols were reviewed and
approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Virginia (Protocol #3677).
Bacterial strains and culture conditions
B. anthracis Sterne strain 7702 spores were prepared using a
liquid culture method [54] with modification. Briefly, Difco
Sporulation Medium [55] was inoculated with B. anthracis 7702,
and cultures were incubated 4–5 d at 37uC with shaking. After
sporulation, cultures were washed in cold, sterile dH2O and heat
treated at 65uC to kill any remaining vegetative cells. Spores were
purified over a Percoll gradient (GE Healthcare Biosciences,
Piscataway, NJ, USA) washed, and enumerated. B. anthracis bacilli
were prepared in brain heart infusion (BHI) broth (Becton,
Figure 6. Detection and quantification of toxemia in spore-
challenged mice. Quantitative measurement of the B. anthracis toxin
component LF in sera collected from moribund animals receiving
CXCL9/CXCL10/CXCL11 neutralizing sera and paired, spore-challenged
animals receiving control serum. Analysis was performed using MALDI-
TOF MS with internal standards (see Materials and Methods).
Concentrations of active LF measured from individual mice are shown;
solid lines represent the median concentration for each group (n=6
animals per group). LF concentrations measured in sera collected from
chemokine-neutralized animals were significantly greater than concen-
trations determined for control mice (p=0.002). Data points along the
X-axis represent values below the limit of detection, 0.005 ng/ml.
doi:10.1371/journal.ppat.1001199.g006
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subcultured prior to use. Luminescent B. anthracis 7702-lux was
kindly provided by Dr. T. Merkel (Food and Drug Administration,
Bethesda, MD) and is described in detail elsewhere [27]. All work
involving B. anthracis Sterne strain 7702 was performed using
appropriate BSL-2 precautions. B. anthracis Ames strain was
obtained through the NIH Biodefense and Emerging Infections
Research Resources Repository, NIAID, NIH: Bacillus anthracis,
Strain Ames (A0462), NR-411. The original stock was grown on
capsulation (CAP) agar plates (0.3% yeast extract, 0.8% nutrient
broth, 1.5% agar, 5% horse serum, and 0.8% sodium bicarbonate)
overnight at 37uC, 5% CO2 in order to isolate phenotypically
encapusulated organisms. Ames strain spores were prepared on
agar slants as previously described [14], and bacilli were prepared
fresh from CAP agar plates. All experiments with B. anthracis Ames
strain were performed under BLS-3 precautions in a Select Agents
approved laboratory following guidelines established by the
Centers for Disease Control and Prevention, the US Department
of Agriculture, and the University of Virginia Institutional
Biosafety Committee.
Antimicrobial assays
For CFU determination and Alamar Blue analysis, spores
(0.421610
6 total) or bacilli (0.423610
5 total) were added to
Dulbecco’s modified essential medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT, USA) and containing 48 mg/ml of recombinant
murine or human CXCL9, CXCL10, CXCL11, CCL2, or CCL5
(Peprotech, Rocky Hill, NJ, USA) stabilized with 0.3% human
serum albumin (ZLB Bioplasma AG, Berne, Switzerland), or an
equal volume of albumin alone (untreated control); recombinant
murine chemokines were used unless otherwise specified. Endpoint
analyses were performed 6 h post-treatment (after spore germina-
tion and/or vegetative outgrowth, but before bacterial overgrowth
in untreated samples) as previously described [22].
Animal model
Wild-type C57BL/6 mice, as well as CXCL10
-/- and CXCR3
-/-
animals were obtained from The Jackson Laboratory (Bar Harbor,
ME, USA). Antibody-mediated neutralization of CXCL9,
CXCL10, CXCL11, and CXCR3 was achieved using published
protocols [23,24]. Briefly, C57BL/6 mice (female, 6–8 weeks old)
were administered i.p. injections of goat serum raised against
recombinant CXCL9, CXCL10, or CXCL11 (R&D Systems,
Minneapolis, MN, USA) or a peptide constituting the NH2
terminus of murine CXCR3; control animals received an equal
volume of donor herd normal goat serum (SeraCare Life Sciences,
Milford, MA, USA). Neutralization was begun 24h prior to spore
challenge, and performed daily throughout the study period
(#20 d). For single ligand or receptor neutralization, animals
received approximately 6 mg of total goat IgG daily; for multiple
ligand neutralization, animals received equal amounts of the
indicated neutralizing sera, approximately 15 mg of total IgG.
Antibody neutralizing capacity and selectivity have been described
previously [23]. Intranasal B. anthracis spore challenges were
performed following sedation with ketamine/xylazine (60/6 mg/
kg body weight, i.p.). Twenty microliters of spore suspension
(126610
7 spores total) was placed drop-wise onto the nares of
mice, and the animals were kept upright until breathing returned
to normal. Animals were monitored for signs of illness according to
an IACUC approved scoring system taking into account activity
level, posture, and respiration; animals determined to be
moribund were euthanized with an overdose of ketamine.
Tissue CFU determination
All tissues used in CFU determination were harvested following
euthanasia and homogenized by hand on ice in sterile PBS.
Sample dilutions were prepared in duplicate, and subsequently
plated on BHI agar (Remel, Lenexa, KS, USA); sample plates
were incubated overnight at room temperature before colony
enumeration. All tissue samples were plated 6 heat treatment at
65uC for 30 min to distinguish between spore and vegetative forms
of B. anthracis.
Bioluminescent imaging
Images of spore-challenged mice and luminescent signals were
acquired using the In Vivo Imaging System (IVIS) Spectrum
(Caliper Life Sciences, Hopkinton, MA, USA). For imaging, mice
were anesthetized with 2.5% isofluorane mixed with oxygen and
delivered by the XGI-8 gas anesthesia system supplied with the
IVIS Spectrum. Images were acquired according to the manufac-
turer’s recommendations, and the emission of photons from live
animals was analyzed using Living Image 2.5 software.
LF detection and quantification
Functional anthrax toxin LF was measured in animal sera
prepared from whole blood collected via cardiac puncture.
Quantification was based on matrix-assisted laser desorption/
ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS)
as previously described [30]. Briefly, MALDI-TOF MS was used
to detect specific peptide products generated following LF-
mediated cleavage of a synthetic peptide substrate; LF concentra-
tions were subsequently determined by isotope-dilution MS.
Statistical analysis
Significant differences among in vitro treatment groups were
determined using one-way ANOVA with a Bonferroni multiple
comparison post test; logarithmic (log10) transformation of CFU
values was performed prior to statistical evaluation. The reported
half maximal effective concentration (EC50) values were deter-
mined using the sigmoidal dose-response equation of nonlinear
regression and are presented as EC50 695% confidence interval.
Significant differences in bacterial counts and LF concentrations
among animal treatment groups were determined using the Mann-
Whitney rank-sum test for non-parametric data. Host survival was
analyzed according to the Kaplan-Meier product limit method;
pair-wise comparisons were made using the log-rank test.
Supporting Information
Figure S1 CXCL9-mediated direct antimicrobial effects against
B. anthracis Sterne strain spores and bacilli are concentration
dependent. B. anthracis spores (A and B) or bacilli (C and D) were
treated with increasing amounts of murine CXCL9 for 6 h before
end point determination, n=3 independent experiments. Alamar
Blue analysis demonstrated concentration-dependent effects and
was used to calculate EC50 values 695% confidence interval; CFU
determination supported these conclusions, (n.d. = none
detected). For clarity, only the lowest CXCL9 concentrations
demonstrating significant decreases as compared to the untreated
control are labeled with asterisks; **p value ,0.01, ***p value
,0.001.
Found at: doi:10.1371/journal.ppat.1001199.s001 (0.82 MB TIF)
Figure S2 CXCR3 neutralizing serum significantly reduces host
cell infiltration in response to CXCL9, CXCL10, and CXCL11 in
vivo. C57BL/6 mice (n=5 per group) received no injection
(untreated) or an i.p. injection of control serum or CXCR3
CXC Chemokines and Pulmonary Infection
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albumin (-) or 10 ng total of each CXCL9, CXCL10, and
CXCL11 (+) via i.p. injection; peritoneal lavage cytology was
performed 6 h after chemokine administration. **p value ,0.01,
***p value ,0.001 between indicated groups.
Found at: doi:10.1371/journal.ppat.1001199.s002 (0.30 MB TIF)
Figure S3 CXCR3 neutralization does not disrupt CXC
chemokine induction in response to B. anthracis spore challenge.
Lung tissue (n=5-6 animals per group per time point) was
harvested from naA ˜¯ve C57BL/6 mice (untreated) or spore-
challenged animals receiving control serum or CXCR3 neutral-
izing serum. ELISA quantification is expressed as median
(interquartile range) chemokine concentration measured in diluted
lung homogenate filtrates.
Found at: doi:10.1371/journal.ppat.1001199.s003 (0.74 MB TIF)
Figure S4 Inflammatory cell populations present in the lungs of
spore-challenged mice receiving CXCL9/CXCL10/CXCL11 or
CXCR3 neutralizing sera are equivalent. Two days post-
challenge, single cell suspensions were prepared from the lungs
of C57BL/6 mice (n=4 animals per group) receiving neutralizing
or control serum. Host cell populations were analyzed by flow
cytometry; the following CD45
+ populations were examined:
neutrophils (CD11b
hi, Gr1
hi); alveolar macrophages (CD11b
neg-lo,
CD11c
hi), CD4
+ T cells (CD3
+, CD4
+); CD8
+ T cells (CD3
+,
CD8
+); B cells (B220
+, CD11c
2); myeloid dendritic cells (CD11b
+,
CD11c
+); airway dendritic cells (CD11c
+, CD103
+); inflammatory
macrophages (CD11b
+, Gr1
neg-lo, CD11c
2, Mac3
+); NK cells
(NK1.1
+, CD3
2). Results are expressed as total numbers of
positive cells within the lungs.
Found at: doi:10.1371/journal.ppat.1001199.s004 (0.74 MB TIF)
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